Threshold Pharmaceuticals Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC

Threshold Pharmaceuticals Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC 
Early Clinical Data on Combinations of TH-302 With Anti-Angiogenic
Therapies in Solid Tumors; Preclinical Data on Combinations of TH-302
With Gemcitabine and Nab-Paclitaxel in Models of Pancreatic Cancer 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/07/13 --  Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data on
its investigational hypoxia-targeted drug, TH-302, will be presented
at the AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics, October 19 - 23, 2013, in Boston, MA. The
presentations will characterize early data from two ongoing clinical
trials evaluating combinations of TH-302 with anti-angiogenic agents
in solid tumors as well as preclinical data on the tolerability and
activity of TH-302, gemcitabine, and nab-paclitaxel combinations in
models of pancreatic cancer.  
New data from a Phase 1 clinical trial combining TH-302 and pazopanib
(Investigator Sponsored Trial 4001) in patients with advanced solid
tumors will be presented in a poster session on Tuesday, October 22
(Abstract #C61). Updated data from a Phase 1/2 clinical trial
combining TH-302 and sunitinib (Study 410) in patients with renal
cell carcinoma, gastrointestinal tumors, or pancreatic neuroendocrine
tumors will be presented in a poster session on Monday, October 21
(Abstract #B77). Emerging preclinical research suggests that
anti-angiogenic therapy may increase tumor hypoxia. These two
clinical trials further characterize the potential of combining
TH-302 with anti-angiogenic agents. 
In addition, results from preclinical research evaluating
combinations of TH-302, gemcitabine, and nab-paclitaxel in xenograft
models of pancreatic cancer will be presented in a poster session on
Tuesday, October 22 (Abstract #C287).  
Abstracts are now available on the 2013 AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics Online
Proceedings and Itinerary Planner Web page, which can be accessed at
About TH-302
 TH-302 is an investigational hypoxia-targeted drug that
is designed to be activated under tumor hypoxic conditions, a
hallmark of many cancers. Areas of low oxygen levels (hypoxia) in
solid tumors are due to insufficient blood supply as a result of
aberrant vasculature. Similarly, the bone marrow of patients with
hematological malignancies has also been shown, in some cases, to be
severely hypoxic. 
TH-302 is currently under evaluation in two Phase 3 trials: one in
combination with doxorubicin versus doxorubicin alone in patients
with soft tissue sarcoma (STS), and the other in combination with
gemcitabine versus gemcitabine and placebo in patients with advanced
pancreatic cancer (MAESTRO). Both Phase 3 trials are being conducted
under Special Protocol Agreements with the U.S. Food and Drug
Administration (FDA). The FDA and the European Commission have
granted TH-302 Orphan Drug Designation for the treatment of STS.
TH-302 is also being investigated in hematological malignancies and
in combination with other therapies in a variety of solid tumors. 
Threshold has a global license and co-development agreement for
TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option
for Threshold to co-commercialize in the U.S. 
About Threshold Pharmaceuticals 
 Threshold Pharmaceuticals, Inc. is
a biotechnology company focused on the discovery and development of
drugs targeting Tumor Hypoxia, the low oxygen condition found in
microenvironments of most solid tumors as well as the bone marrows of
some hematologic malignancies. This approach offers broad potential
to treat a variety of cancers. By selectively targeting tumor cells,
we are building a pipeline of drugs that hold promise to be more
effective and less toxic to healthy tissues than conventional
anticancer drugs. For additional information, please visit our
website ( 
Forward-Looking Statements
 Except for statements of historical fact,
the statements in this press release are forward-looking statements,
including statements regarding the potential therapeutic uses and
benefits of its product candidates. These statements involve risks
and uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, Threshold's ability to
enroll or complete its anticipated clinical trials, the time and
expense required to conduct such clinical trials and analyze data,
issues arising in the regulatory or manufacturing process and the
results of such clinical trials (including product safety issues and
efficacy results). Further information regarding these and other
risks is included under the heading "Risk Factors" in Threshold's
Quarterly Report on Form 10-Q, which has been filed with the
Securities and Exchange Commission on August 1, 2013 and is available
from the SEC's website ( and on our website
( under the heading "Investors." We undertake
no duty to update any forward-looking statement made in this news
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
Press spacebar to pause and continue. Press esc to stop.